KR20230167897A - Composition for the prevention, improvement or treatment of atopy comprising Moringa concanensis L. as an active ingredient - Google Patents
Composition for the prevention, improvement or treatment of atopy comprising Moringa concanensis L. as an active ingredient Download PDFInfo
- Publication number
- KR20230167897A KR20230167897A KR1020220068108A KR20220068108A KR20230167897A KR 20230167897 A KR20230167897 A KR 20230167897A KR 1020220068108 A KR1020220068108 A KR 1020220068108A KR 20220068108 A KR20220068108 A KR 20220068108A KR 20230167897 A KR20230167897 A KR 20230167897A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- present
- composition
- atopy
- concanensis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 241000339400 Moringa concanensis Species 0.000 title claims abstract description 65
- 206010003645 Atopy Diseases 0.000 title claims abstract description 39
- 239000004480 active ingredient Substances 0.000 title claims abstract description 31
- 238000011282 treatment Methods 0.000 title description 16
- 230000006872 improvement Effects 0.000 title description 6
- 230000002265 prevention Effects 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 76
- 239000002537 cosmetic Substances 0.000 claims abstract description 31
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 235000013376 functional food Nutrition 0.000 claims abstract description 17
- 230000036541 health Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 5
- 230000026731 phosphorylation Effects 0.000 claims description 5
- 238000006366 phosphorylation reaction Methods 0.000 claims description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 4
- 108010057466 NF-kappa B Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims description 3
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 3
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 231100000065 noncytotoxic Toxicity 0.000 claims 1
- 230000002020 noncytotoxic effect Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 19
- 210000003630 histaminocyte Anatomy 0.000 abstract description 6
- 230000008595 infiltration Effects 0.000 abstract description 6
- 238000001764 infiltration Methods 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 3
- 210000002615 epidermis Anatomy 0.000 abstract description 3
- 230000002860 competitive effect Effects 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 20
- 238000000034 method Methods 0.000 description 15
- -1 IL-1β Proteins 0.000 description 13
- 230000003110 anti-inflammatory effect Effects 0.000 description 13
- 206010012438 Dermatitis atopic Diseases 0.000 description 12
- 201000008937 atopic dermatitis Diseases 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 235000013305 food Nutrition 0.000 description 11
- 210000002510 keratinocyte Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 235000013355 food flavoring agent Nutrition 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 239000006071 cream Substances 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- 235000010356 sorbitol Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 4
- 102100023118 Transcription factor JunD Human genes 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000000638 solvent extraction Methods 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000013538 functional additive Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000046109 Sorghum vulgare var. nervosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000028 nontoxic concentration Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명의 모링가 콘카넨시스(Moringa concanensis L.) 주정 추출물을 유효성분으로 포함하는 조성물은 독성이 없고, IgE 생성을 효과적으로 억제시키며, 아토피로 인해 발생하는 경피 수분 손실, 비만세포의 침윤 감소 및 표피 두께 감소시키는 등 아토피를 예방, 개선 또는 치료시키는 효능이 매우 뛰어나, 경쟁력 있는 화장품, 건강기능식품 또는 의약품 등의 제조에 유용하게 이용될 수 있다.The composition containing Moringa concanensis L. alcohol extract of the present invention as an active ingredient is non-toxic, effectively inhibits IgE production, reduces transdermal water loss caused by atopy, and mast cell infiltration. It has excellent efficacy in preventing, improving or treating atopy, including reducing the thickness of the epidermis, and can be usefully used in the manufacture of competitive cosmetics, health functional foods or pharmaceuticals.
Description
본 발명은 모링가 콘카넨시스(Moringa concanensis L.)를 유효성분으로 포함하는 아토피의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, improving or treating atopy containing Moringa concanensis L. as an active ingredient.
아토피 피부염은 대표적인 만성 알레르기성 피부 염증질환으로 주로 소양감, 홍반, 부종, 삼출물, 부스럼 등의 증상이 발생하며, 환경적 항원 및 자극물질 등에 의해 증상이 악화될 수 있는 질환이다. 아토피 피부염으로 진단받은 사람의 비율이 성인에서는 3.4%, 1-18세에서는 15.7%로 유아기와 소아기에 주로 나타나는 것으로 보고되었다. 아토피 피부염의 발병 원인은 명확하게 밝혀지지 않았지만, 유전학적, 환경적, 면역학적 요인 등과 같이 여러 가지 인자의 상호작용 때문이라고 추측되고 있다. 그렇기 때문에 발병 요인 중 하나의 치료만으로는 효과적인 개선을 얻기 힘든 질환이다. 또한, 아토피 피부염은 뚜렷한 치료방법이 제시되지 않았으며, 만성적이고 쉽게 재발한다는 특징 때문에 예방과 관리에 대한 중요성이 부각되고 있다. 현재 제공되는 치료 방법으로는 습윤 드레싱, 경구 및 주사 스테로이드, 면역 조절제 등이 있으나 그에 따른 부작용 발생으로 환자들이 기피하는 경향이 있다.Atopic dermatitis is a representative chronic allergic skin inflammatory disease that mainly causes symptoms such as itching, erythema, edema, exudate, and swelling, and the symptoms can be worsened by environmental antigens and irritants. It has been reported that the proportion of people diagnosed with atopic dermatitis is 3.4% in adults and 15.7% in those aged 1 to 18, and it mainly occurs in infancy and childhood. Although the cause of atopic dermatitis is not clearly known, it is believed to be due to the interaction of various factors such as genetic, environmental, and immunological factors. Therefore, it is difficult to achieve effective improvement by treating only one of the causative factors. In addition, no clear treatment method has been proposed for atopic dermatitis, and the importance of prevention and management is highlighted due to its chronic and easily recurring characteristics. Currently available treatment methods include wet dressings, oral and injectable steroids, and immunomodulators, but patients tend to avoid them due to side effects.
이러한 배경 하에서 본 발명자들은 아토피의 예방, 개선 또는 치료 효과를 나타내며 부작용이 적은 천연물을 찾고자 예의 노력한 결과, 기존에 아토피 피부염에 대한 효능이 잘 알려지지 않았던 모링가 콘카넨시스(Moringa concanensis L.)를 이용하여 아토피에 대한 개선 또는 치료 효과를 확인하였다. 그 결과 모링가 콘카넨시스 주정 추출물이 아토피 동물 모델에서 체중 감소와 같은 부작용이 없고, IgE 생성, 표피 두께 및 비만세포 침윤을 효과적으로 감소시키는 등 아토피의 개선 또는 치료 효과를 확인함으로써, 본 발명을 완성하게 되었다.Under this background, the present inventors made diligent efforts to find a natural product that prevents, improves, or treats atopy and has fewer side effects. As a result, they used Moringa concanensis L., whose efficacy against atopic dermatitis was not previously well known. The improvement or treatment effect on atopy was confirmed. As a result, the Moringa concanensis alcohol extract was confirmed to have an improvement or treatment effect on atopy, such as having no side effects such as weight loss and effectively reducing IgE production, epidermal thickness, and mast cell infiltration in an atopic animal model, thereby completing the present invention. I did it.
본 발명의 목적은 모링가 콘카넨시스 추출물을 유효성분으로 포함하는 아토피의 예방 또는 개선용 화장료 조성물을 제공하는 것이다.The purpose of the present invention is to provide a cosmetic composition for preventing or improving atopy containing Moringa concanensis extract as an active ingredient.
또한, 본 발명의 목적은 모링가 콘카넨시스 추출물을 유효성분으로 포함하는 아토피의 예방 또는 개선용 건강기능식품 조성물을 제공하는 것이다.Additionally, an object of the present invention is to provide a health functional food composition for preventing or improving atopy containing Moringa concanensis extract as an active ingredient.
마지막으로, 본 발명의 목적은 모링가 콘카넨시스 추출물을 유효성분으로 포함하는 아토피의 예방 또는 치료용 약학 조성물을 제공하는 것이다.Lastly, the purpose of the present invention is to provide a pharmaceutical composition for preventing or treating atopy containing Moringa concanensis extract as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 모링가 콘카넨시스 추출물을 유효성분으로 포함하는 아토피의 예방 또는 개선용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for preventing or improving atopy containing Moringa concanensis extract as an active ingredient.
본 발명의 일 실시예에 있어서, 상기 추출물은 열수 추출법 또는 휘발성 용제를 이용한 유기용매 추출법을 이용하여 추출한 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the extract may be extracted using a hot water extraction method or an organic solvent extraction method using a volatile solvent, but is not limited thereto.
본 발명의 일 실시예에 있어서, 상기 유기용매 추출법은 에탄올을 용매로 이용한 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the organic solvent extraction method may use ethanol as a solvent, but is not limited thereto.
본 발명의 일 실시예에 있어서, 상기 조성물은 NO 및 PGE2 생성을 억제시키는 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the composition may inhibit NO and PGE 2 production, but is not limited thereto.
본 발명의 일 실시예에 있어서, 상기 조성물은 iNOS와 COX-2의 발현을 억제시키는 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the composition may inhibit the expression of iNOS and COX-2, but is not limited thereto.
본 발명의 일 실시예에 있어서, 상기 조성물은 TNF-α, IL-1β 및 IL-6의 발현을 억제시키는 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the composition may inhibit the expression of TNF-α, IL-1β, and IL-6, but is not limited thereto.
본 발명의 일 실시예에 있어서, 상기 조성물은 NF-κB, JNK 및 AP-1의 인산화를 억제시키는 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the composition may inhibit phosphorylation of NF-κB, JNK, and AP-1, but is not limited thereto.
본 발명의 일 실시예에 있어서, 상기 조성물은 혈중 IgE 농도를 감소시키는 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the composition may reduce the concentration of IgE in the blood, but is not limited thereto.
본 발명의 일 실시예에 있어서, 상기 모링가 콘카넨시스 추출물은 모링가 콘카넨시스의 잎 부분을 추출한 것일 수 있으나, 이에 한정되는 것은 아니다.In one embodiment of the present invention, the Moringa concanensis extract may be extracted from the leaf portion of Moringa concanensis, but is not limited thereto.
또한, 본 발명은 모링가 콘카넨시스 추출물을 유효성분으로 포함하는 아토피의 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving atopy containing Moringa concanensis extract as an active ingredient.
마지막으로, 본 발명은 모링가 콘카넨시스 추출물을 유효성분으로 포함하는 아토피의 예방 또는 치료용 약학 조성물을 제공한다.Finally, the present invention provides a pharmaceutical composition for preventing or treating atopy containing Moringa concanensis extract as an active ingredient.
본 발명의 모링가 콘카넨시스(Moringa concanensis L.) 주정 추출물을 유효성분으로 포함하는 조성물은 독성이 없고, IgE 생성을 효과적으로 억제시키며, 아토피로 인해 발생하는 경피 수분 손실, 비만세포의 침윤 감소 및 표피 두께 감소시키는 등 아토피를 예방, 개선 또는 치료시키는 효능이 매우 뛰어나, 경쟁력 있는 화장품, 건강기능식품 또는 의약품 등의 제조에 유용하게 이용될 수 있다.The composition containing Moringa concanensis L. alcohol extract of the present invention as an active ingredient is non-toxic, effectively inhibits IgE production, reduces transdermal water loss caused by atopy, and mast cell infiltration. It has excellent efficacy in preventing, improving or treating atopy, including reducing the thickness of the epidermis, and can be usefully used in the manufacture of competitive cosmetics, health functional foods or pharmaceuticals.
도 1은 본 발명의 일 실시예에 있어서, 각질형성세포에 모링가 콘카넨시스 주정 추출물 처리 후 세포독성을 확인한 그래프이다.
도 2는 본 발명의 일 실시예에 있어서, 각질형성세포에 모링가 콘카넨시스 주정 추출물 처리 후 염증반응을 유도하였을 때 염증매개인자의 생성을 나타낸 그래프이다.
도 3은 본 발명의 일 실시예에 있어서, 각질형성세포에 모링가 주정 콘카넨시스 추출물 처리 후 염증반응을 유도하였을 때 염증매개인자의 합성에 관여하는 효소의 발현을 나타낸 그래프이다.
도 4는 본 발명의 일 실시예에 있어서, 각질형성세포에 모링가 콘카넨시스 주정 추출물 처리 후 염증반응을 유도하였을 때 염증성 사이토카인의 발현을 나타낸 그래프이다.
도 5는 본 발명의 일 실시예에 있어서, 각질형성세포에 모링가 콘카넨시스 주정 추출물 처리 후 염증반응을 유도하였을 때 염증반응에 관여하는 전사인자의 인산화를 나타낸 그래프이다.
도 6은 본 발명의 일 실시예에 있어서, 아토피 유발 마우스에 모링가 콘카넨시스 주정 추출물 처리 전후의 피부 상태를 확인한 사진이다.
도 7은 본 발명의 일 실시예에 있어서, 아토피 유발 마우스에 실시예 및 비교예에 따른 모링가 콘카넨시스 주정 추출물을 처리한 후 아토피 증상의 정도를 기준에 따라 점수로 나타낸 그래프이다.
도 8은 본 발명의 일 실시예에 있어서, 아토피 유발 마우스에 실시예 및 비교예에 따른 모링가 콘카넨시스 주정 추출물을 처리한 후 귀 두께를 측정하여 나타낸 그래프이다.
도 9는 본 발명의 일 실시예에 있어서, 아토피 유발 마우스에 실시예 및 비교예에 따른 모링가 콘카넨시스 주정 추출물을 처리한 후 피부의 수분 손실 정도를 측정하여 나타낸 그래프이다.
도 10은 본 발명의 일 실시예에 있어서, 아토피 유발 마우스에 실시예 및 비교예에 따른 모링가 콘카넨시스 주정 추출물을 처리한 후 체중 변화를 나타낸 그래프이다.
도 11은 본 발명의 일 실시예에 있어서, 아토피 유발 마우스에 실시예 및 비교예에 따른 모링가 콘카넨시스 주정 추출물을 처리한 후 혈액에서 IgE 발현량을 나타낸 그래프이다.
도 12는 본 발명의 일 실시예에 있어서, 아토피 유발 마우스에 실시예 및 비교예에 따른 모링가 콘카넨시스 주정 추출물을 처리한 후 부검을 통해 면역세포의 활성과 관련 있는 비장의 무게를 나타낸 그래프이다.
도 13, 14 및 15는 본 발명의 일 실시예에 있어서, 아토피 유발 마우스에 실시예 및 비교예에 따른 모링가 콘카넨시스 주정 추출물을 처리한 후 H&E와 Toluidine blue staining을 통해 각각 표피의 두께와 비만세포의 침윤을 염색하여 확인한 사진과 그래프이다.
도 16은 본 발명의 일 실시예에 있어서, 모링가 콘카넨시스의 추출 용매에 따른 항염증 효과를 비교한 그래프이다.
도 17은 본 발명의 일 실시예에 있어서, 모링가 콘카넨시스의 부위별 세포독성평가 및 항염증 효과를 비교한 그래프이다.Figure 1 is a graph confirming cytotoxicity after treatment of Moringa concanensis alcohol extract on keratinocytes in an embodiment of the present invention.
Figure 2 is a graph showing the production of inflammatory mediators when an inflammatory response is induced in keratinocytes after treatment with Moringa concanensis alcohol extract in one embodiment of the present invention.
Figure 3 is a graph showing the expression of enzymes involved in the synthesis of inflammatory mediators when an inflammatory response is induced in keratinocytes after treatment with Moringa concanensis extract in an embodiment of the present invention.
Figure 4 is a graph showing the expression of inflammatory cytokines when an inflammatory response is induced in keratinocytes after treatment with Moringa concanensis alcohol extract in one embodiment of the present invention.
Figure 5 is a graph showing the phosphorylation of transcription factors involved in the inflammatory response when an inflammatory response is induced in keratinocytes after treatment with Moringa concanensis alcohol extract in an embodiment of the present invention.
Figure 6 is a photograph confirming the skin condition before and after treatment of Moringa concanensis alcohol extract in an atopy-induced mouse, in an embodiment of the present invention.
Figure 7 is a graph showing the degree of atopy symptoms as a score according to standards after treating atopy-inducing mice with the Moringa concanensis alcohol extract according to the Examples and Comparative Examples, in an embodiment of the present invention.
Figure 8 is a graph showing the measurement of ear thickness after treating atopy-induced mice with the Moringa concanensis alcohol extract according to Examples and Comparative Examples, in an embodiment of the present invention.
Figure 9 is a graph showing the degree of moisture loss in the skin after treating atopy-prone mice with the Moringa concanensis alcohol extract according to the Examples and Comparative Examples, according to an embodiment of the present invention.
Figure 10 is a graph showing the change in body weight after treating atopy-induced mice with Moringa concanensis alcohol extract according to Examples and Comparative Examples, in one embodiment of the present invention.
Figure 11 is a graph showing the level of IgE expression in the blood after treating atopy-induced mice with the Moringa concanensis alcohol extract according to the Examples and Comparative Examples, according to an embodiment of the present invention.
Figure 12 is a graph showing the weight of the spleen related to the activity of immune cells through autopsy after treating atopy-induced mice with the Moringa concanensis alcohol extract according to the Examples and Comparative Examples in an embodiment of the present invention. am.
Figures 13, 14, and 15 show the thickness and thickness of the epidermis through H&E and Toluidine blue staining, respectively, after treating atopy-induced mice with the Moringa concanensis alcohol extract according to the Examples and Comparative Examples, in an embodiment of the present invention. These are photos and graphs confirming the infiltration of mast cells by staining.
Figure 16 is a graph comparing the anti-inflammatory effect according to the extraction solvent of Moringa concanensis in one embodiment of the present invention.
Figure 17 is a graph comparing the cytotoxicity evaluation and anti-inflammatory effect of Moringa concanensis by site in one embodiment of the present invention.
이하, 첨부된 도면을 참조하여 본 발명의 구현예로 본 발명을 상세히 설명하기로 한다. 다만, 하기 구현 예는 본 발명에 대한 예시로 제시되는 것으로, 당업자에게 주지 저명한 기술 또는 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우에는 그 상세한 설명을 생략할 수 있고, 이에 의해 본 발명이 제한되지는 않는다. 본 발명은 후술하는 특허 청구범위의 기재 및 그로부터 해석되는 균등 범주 내에서 다양한 변형 및 응용이 가능하다.Hereinafter, the present invention will be described in detail through embodiments of the present invention with reference to the attached drawings. However, the following implementation examples are provided as examples of the present invention, and if it is judged that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description may be omitted. , the present invention is not limited thereby. The present invention is capable of various modifications and applications within the description of the patent claims described below and the scope of equivalents interpreted therefrom.
또한, 본 명세서에서 사용되는 용어(terminology)들은 본 발명의 바람직한 실시 예를 적절히 표현하기 위해 사용된 용어들로서, 이는 사용자, 운용자의 의도 또는 본 발명이 속하는 분야의 관례 등에 따라 달라질 수 있다. 따라서 본 용어들에 대한 정의는 본 명세서 전반에 걸친 내용을 토대로 내려져야 할 것이다. 명세서 전체에서, 어떤 부분이 어떤 구성요소를 "포함"한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성 요소를 더 포함할 수 있는 것을 의미한다.In addition, the terminology used in this specification is a term used to appropriately express preferred embodiments of the present invention, and may vary depending on the intention of the user or operator or the customs of the field to which the present invention belongs. Therefore, definitions of these terms should be made based on the content throughout this specification. Throughout the specification, when a part is said to “include” a certain element, this means that it may further include other elements rather than excluding other elements, unless specifically stated to the contrary.
본 명세서 전체에 걸쳐, 특정 물질의 농도를 나타내기 위하여 사용되는 '%'는 별도의 언급이 없는 경우, 고체/고체는 (w/w) %, 고체/액체는 (w/v) %, 그리고 액체/액체는 (v/v) %이다.Throughout this specification, '%' used to indicate the concentration of a specific substance means (w/w) % for solid/solid, (w/v) % for solid/liquid, and Liquid/liquid is (v/v) %.
일 측면에서, 본 발명은 모링가 콘카넨시스 추출물을 유효성분으로 포함하는 아토피의 예방 또는 개선용 화장료 조성물에 관한 것이다.In one aspect, the present invention relates to a cosmetic composition for preventing or improving atopy containing Moringa concanensis extract as an active ingredient.
본 발명에 따른 추출물은 당업계에 공지된 추출 및 분리방법을 사용하여 천연으로부터 추출 및 분리하여 수득한 것을 사용할 수 있으며, 본 발명에서 정의된 "추출물"은 적절한 용매를 이용하여 모링가 콘카넨시스로부터 추출한 것이며, 예를 들어, 조추출물, 극성용매 가용 추출물 또는 비극성용매 가용 추출물을 모두 포함한다. 상기 모링가 콘카넨시스로부터 추출물을 추출하기 위한 적절한 용매로는 화장품학 또는 식품학적으로 허용되는 유기용매라면 어느 것을 사용해도 무방하며, 물 또는 유기용매를 사용할 수 있으며, 이에 제한되지는 않으나, 예를 들어, 정제수, 메탄올(Methanol), 에탄올(Ethanol), 프로판올(Propanol), 이소프로판올(Isopropanol), 부탄올(Butanol) 등을 포함하는 탄소수 1 내지 4의 알콜, 아세톤(Acetone), 에테르(Ether), 벤젠(Benzene), 클로로포름(Chloroform), 에틸아세테이트(Ethyl acetate), 메틸렌클로라이드(Methylene chloride), 헥산(Hexane) 및 시클로헥산 (Cyclohexane) 등의 각종 용매를 단독으로 혹은 혼합하여 사용할 수 있다. 추출 방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 방법 중 어느 하나를 선택하여 사용할 수 있다. 또한, 목적하는 추출물은 추가로 통상의 분획 공정을 수행할 수도 있으며, 통상의 정제 방법을 이용하여 정제될 수도 있다.The extract according to the present invention can be obtained by extracting and separating from nature using extraction and separation methods known in the art, and "extract" as defined in the present invention is Moringa concanensis using an appropriate solvent. It is extracted from, and includes, for example, crude extract, polar solvent-soluble extract, or non-polar solvent-soluble extract. The appropriate solvent for extracting the extract from Moringa concanensis may be any organic solvent acceptable from cosmetics or food science, and water or an organic solvent may be used, but is not limited thereto, for example. For example, alcohols with 1 to 4 carbon atoms including purified water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, and benzene. Various solvents such as Benzene, Chloroform, Ethyl acetate, Methylene chloride, Hexane, and Cyclohexane can be used individually or in combination. As an extraction method, any one of the following methods can be selected and used: hot water extraction, cold needle extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, and compression. In addition, the desired extract may be further subjected to a conventional fractionation process or may be purified using a conventional purification method.
본 발명의 추출물의 제조방법에는 제한이 없으며, 공지되어 있는 어떠한 방법도 이용될 수 있다. 예를 들면, 본 발명의 조성물에 포함되는 추출물은 상기한 열수 추출 또는 용매 추출법으로 추출된 1차 추출물을, 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말상태로 제조할 수 있다. 또한 상기 1차 추출물을 실리카겔 컬럼 크로마토그래피(Silica gel column chromatography), 박층 크로마토그래피(Thin layer chromatography), 고성능 액체 크로마토그래피(High performance liquid chromatography) 등과 같은 다양한 크로마토그래피를 이용하여 추가로 정제된 분획을 얻을 수도 있다. 따라서, 본 발명에 있어서 추출물은 추출, 분획 또는 정제의 각 단계에서 얻어지는 모든 추출액, 분획 및 정제물, 그들의 희석액, 농축액 또는 건조물을 모두 포함하는 개념이다.There is no limitation to the method for producing the extract of the present invention, and any known method can be used. For example, the extract included in the composition of the present invention can be prepared in powder form from the primary extract extracted by the above-described hot water extraction or solvent extraction method by additional processes such as reduced pressure distillation and freeze-drying or spray drying. In addition, the primary extract was further purified into fractions using various chromatographies such as silica gel column chromatography, thin layer chromatography, and high performance liquid chromatography. You can also get it. Therefore, in the present invention, extract is a concept that includes all extracts, fractions, and purifications obtained at each stage of extraction, fractionation, or purification, as well as their dilutions, concentrates, or dried products.
본 발명의 "화장료 조성물"은 상술한 본 발명의 모링가 콘카넨시스에서 추출한 추출물의 화장품학적 유효량(Cosmetically effective amount) 및 화장품학적으로 허용되는 담체를 포함하여 제조할 수 있다.The “cosmetic composition” of the present invention can be prepared by containing a cosmetically effective amount of the extract extracted from Moringa concanensis of the present invention described above and a cosmetically acceptable carrier.
본 명세서에서 "화장품학적 유효량"은 상술한 본 발명의 조성물의 항산화 효능을 달성하는 데 충분한 양을 의미한다.As used herein, “cosmetically effective amount” means an amount sufficient to achieve the antioxidant effect of the composition of the present invention described above.
화장료 조성물의 외형은 화장품학 또는 피부과학적으로 허용 가능한 매질 또는 기제를 함유한다. 이는 국소적용에 적합한 모든 제형으로, 예를 들면, 용액, 겔, 고체, 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는, 이온형(리포좀) 및 비이온형의 소낭 분산제의 형태로, 또는 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태로 제공될 수 있다. 이들 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다. 본 발명에 따른 조성물은 또한 포말(Foam)의 형태로 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 사용될 수 있다.The appearance of the cosmetic composition contains a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, such as solutions, gels, solids, pasty anhydrous products, emulsions obtained by dispersing the oil phase in the water phase, suspensions, microemulsions, microcapsules, microgranules or ionic forms (liposomes) and It may be provided in the form of a non-ionic vesicular dispersion, or in the form of a cream, skin, lotion, powder, ointment, spray or concealer stick. These compositions can be prepared according to conventional methods in the art. The composition according to the invention can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
본 발명의 일 실시예에 따른 상기 화장료 조성물은 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들면, 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 파우더, 바디로션, 바디크림, 바디오일 및 바디에센스 등의 화장품으로 제형화될 수 있다.The cosmetic composition according to an embodiment of the present invention is not particularly limited in its formulation, and includes, for example, softening lotion, astringent lotion, nourishing lotion, nourishing cream, massage cream, essence, eye cream, eye essence, and cleansing lotion. It can be formulated into cosmetics such as cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, body oil, and body essence.
본 발명의 화장료 조성물의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물섬유, 식물섬유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a paste, cream or gel, animal fiber, vegetable fiber, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. are used as carrier ingredients. This can be used.
본 발명의 화장료 조성물의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the cosmetic composition of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder can be used as the carrier ingredient. In particular, when the cosmetic composition is a spray, chlorofluorohydride may be used additionally. May contain propellants such as carbon, propane/butane or dimethyl ether.
본 발명의 화장료 조성물의 제형이 용액 또는 유탁액의 경우에는 담체 성분으로서 용매, 용매화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the cosmetic composition of the present invention is a solution or emulsion, a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene. These include fatty acid esters of glycol, 1,3-butylglycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitan.
본 발명의 화장료 조성물의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, the carrier component includes water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used.
본 발명의 화장료 조성물의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알콜 설페이트, 지방족 알콜 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알콜, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 리놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleansing agent, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, and sarcosinate are used as carrier ingredients. , fatty acid amide ether sulfate, alkylamidobetaine, fatty alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linoline derivative, or ethoxylated glycerol fatty acid ester can be used.
본 발명의 화장료 조성물은 스킨, 로션, 크림, 에센스, 팩, 파운데이션, 색조화장품, 선크림, 투웨이케이크, 페이스파우더, 콤팩트, 메이크업베이스, 스킨커버, 아이쉐도우, 립스틱, 립글로스, 립픽스, 아이브로우 펜슬, 화장수 등의 화장품 및 샴푸, 비누 등의 세정제에 적용될 수 있다.The cosmetic composition of the present invention includes skin, lotion, cream, essence, pack, foundation, color cosmetics, sunscreen, two-way cake, face powder, compact, makeup base, skin cover, eye shadow, lipstick, lip gloss, lip fix, and eyebrow pencil. , can be applied to cosmetics such as lotion and detergents such as shampoo and soap.
본 발명의 일 실시예에 따른 화장료 조성물에는 상기 모링가 콘카넨시스에서 추출한 추출물 이외에 기능성 첨가물 및 일반적인 화장료 조성물에 포함되는 성분이 추가로 포함될 수 있다. 상기 기능성 첨가물로는 수용성 비타민, 유용성 비타민, 고분자 펩티드, 고분자 다당, 스핑고 지질 및 해초 엑기스로 이루어진 군에서 선택된 성분을 포함할 수 있다.The cosmetic composition according to an embodiment of the present invention may further include functional additives and components included in general cosmetic compositions in addition to the extract extracted from Moringa concanensis. The functional additive may include ingredients selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingolipids, and seaweed extract.
본 발명의 화장료 조성물에는 또한, 상기 기능성 첨가물과 더불어 필요에 따라 일반적인 화장료 조성물에 포함되는 성분을 배합해도 된다. 이외에 포함되는 배합 성분으로서는 유지 성분, 보습제, 에몰리엔트제, 계면 활성제, 유기 및 무기 안료, 유기 분체, 자외선 흡수제, 방부제, 살균제, 산화 방지제, 식물 추출물, pH 조정제, 알콜, 색소, 향료, 혈행 촉진제, 냉감제, 제한(制汗)제, 정제수 등을 들 수 있다.In addition to the above-mentioned functional additives, the cosmetic composition of the present invention may also contain components included in general cosmetic compositions, if necessary. Other ingredients included include oils and fats, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, disinfectants, antioxidants, plant extracts, pH adjusters, alcohol, pigments, fragrances, and blood circulation agents. Examples include accelerators, cooling agents, restrictors, and purified water.
일 측면에서, 본 방명은 모링가 콘카넨시스 추출물을 유효성분으로 포함하는 아토피의 예방 또는 개선용 건강기능식품 조성물에 관한 것이다.In one aspect, the present invention relates to a health functional food composition for preventing or improving atopy containing Moringa concanensis extract as an active ingredient.
본 발명의 건강기능식품 조성물은 유효성분인 추출물을 함유하는 것 외에 통상의 식품 조성물과 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.In addition to containing the extract as an active ingredient, the health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients like a typical food composition.
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 향미제는 천연 향미제(타우마틴), 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 본 발명의 식품 조성물은 하기 약학적 조성물과 동일한 방식으로 제제화 되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알콜 음료류, 비타민 복합제 및 건강보조식품류 등이 있다.Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose, etc.; Disaccharides such as maltose, sucrose, etc.; and polysaccharides, such as common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The above-described flavoring agents include natural flavoring agents (thaumatin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.). The food composition of the present invention can be formulated in the same manner as the pharmaceutical composition below and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes, health supplements, etc. There is.
또한, 상기 식품 조성물은 유효성분인 추출물 외에 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 식품 조성물은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition, the food composition contains, in addition to the extract as the active ingredient, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and thickening agents (cheese, chocolate, etc.), pectic acid, and salts thereof. , alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. In addition, the food composition of the present invention may contain pulp for the production of natural fruit juice and fruit juice drinks and vegetable drinks.
본 발명의 건강기능식품 조성물은, 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공될 수 있다. 본 발명에서 '건강기능식품 조성물'이라 함은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 말하며, 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다. 본 발명의 건강 기능성 식품은 통상의 식품 첨가물을 포함할 수 있으며, 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다. 상기 '식품 첨가물 공전'에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료 제제, 타르색소제제 등의 혼합제제류 등을 들 수 있다. 예를 들어, 정제 형태의 건강 기능성 식품은 본 발명의 유효성분을 부형제, 결합제, 붕해제 및 다른 첨가제와 혼합한 혼합물을 통상의 방법으로 과립화한 다음, 활택제 등을 넣어 압축성형하거나, 상기 혼합물을 직접 압축 성형할 수 있다. 또한 상기 정제 형태의 건강 기능성 식품은 필요에 따라 교미제 등을 함유할 수도 있다. 캅셀 형태의 건강 기능성 식품 중 경질 캅셀제는 통상의 경질 캅셀에 본 발명의 유효성분을 부형제 등의 첨가제와 혼합한 혼합물을 충진하여 제조할 수 있으며, 연질 캅셀제는 본 발명의 유효성분을 부형제 등의 첨가제와 혼합한 혼합물을 젤라틴과 같은 캅셀 기제에 충진하여 제조할 수 있다. 상기 연질 캅셀제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다. 환 형태의 건강 기능성 식품은 본 발명의 유효성분과 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 성형하여 조제할 수 있으며, 필요에 따라 백당이나 다른 제피제로 제피할 수 있으며, 또는 전분, 탈크와 같은 물질로 표면을 코팅할 수도 있다. 과립 형태의 건강 기능성 식품은 본 발명의 유효성분의 부형제, 결합제, 붕해제 등을 혼합한 혼합물을 기존에 공지된 방법으로 입상으로 제조할 수 있으며, 필요에 따라 착향제, 교미제 등을 함유할 수 있다.The health functional food composition of the present invention can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. In the present invention, 'health functional food composition' refers to food manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with Act No. 6727 on Health Functional Food, and refers to food that is manufactured and processed with respect to the structure and function of the human body. It means taking it for the purpose of controlling nutrients or obtaining useful health effects such as physiological effects. The health functional food of the present invention may contain common food additives, and its suitability as a food additive is determined according to the general rules and general test methods of the food additive code approved by the Ministry of Food and Drug Safety, unless otherwise specified. Determination is made according to relevant standards and standards. Items listed in the 'Food Additive Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; Natural additives such as dark pigment, licorice extract, crystalline cellulose, kaoliang pigment, and guar gum; Examples include mixed preparations such as sodium L-glutamate preparations, noodle additive alkaline preparations, preservative preparations, and tar coloring preparations. For example, health functional foods in the form of tablets are prepared by granulating a mixture of the active ingredient of the present invention with excipients, binders, disintegrants and other additives in a conventional manner, adding a lubricant, etc., and compression molding, or The mixture can be directly compression molded. Additionally, the health functional food in tablet form may contain a flavoring agent, etc., if necessary. Among capsule-type health functional foods, hard capsules can be manufactured by filling a regular hard capsule with a mixture of the active ingredient of the present invention mixed with additives such as excipients, and soft capsules can be prepared by mixing the active ingredient of the present invention with additives such as excipients. It can be manufactured by filling the mixture with a capsule base such as gelatin. The soft capsule may contain plasticizers such as glycerin or sorbitol, colorants, preservatives, etc., if necessary. The health functional food in the form of a ring can be prepared by molding a mixture of the active ingredient of the present invention and excipients, binders, disintegrants, etc. by a previously known method, and can be coated with white sugar or other coating agent as needed. Alternatively, the surface can be coated with substances such as starch or talc. Health functional food in the form of granules can be manufactured into granules by mixing a mixture of excipients, binders, disintegrants, etc. of the active ingredients of the present invention by a known method, and may contain flavoring agents, flavoring agents, etc., if necessary. You can.
일 측면에서, 본 발명은 모링가 콘카넨시스 추출물을 유효성분으로 포함하는 아토피의 예방 또는 치료용 약학 조성물에 관한 것이다.In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating atopy containing Moringa concanensis extract as an active ingredient.
본 발명의 약학 조성물에는 유효성분 이외에 보조제(adjuvant)를 추가로 포함할 수 있다. 상기 보조제는 당해 기술분야에 알려진 것이라면 어느 것이나 제한 없이 사용할 수 있으나, 예를 들어 프로인트(Freund)의 완전 보조제 또는 불완전 보조제를 더 포함하여 그 면역성을 증가시킬 수 있다.The pharmaceutical composition of the present invention may further include adjuvants in addition to the active ingredients. Any adjuvant known in the art may be used without limitation, but, for example, Freund's complete adjuvant or incomplete adjuvant may be further included to increase immunity.
본 발명에 따른 약학 조성물은 유효성분을 약학적으로 허용된 담체에 혼입시킨 형태로 제조될 수 있다. 여기서, 약학적으로 허용된 담체는 제약 분야에서 통상 사용되는 담체, 부형제 및 희석제를 포함한다. 본 발명의 약학 조성물에 이용할 수 있는 약학적으로 허용된 담체는 이들로 제한되는 것은 아니지만, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로스, 메틸 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.The pharmaceutical composition according to the present invention can be prepared by incorporating the active ingredient into a pharmaceutically acceptable carrier. Here, pharmaceutically acceptable carriers include carriers, excipients, and diluents commonly used in the pharmaceutical field. Pharmaceutically acceptable carriers that can be used in the pharmaceutical composition of the present invention include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, Examples include calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀전, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.The pharmaceutical composition of the present invention can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injection solutions according to conventional methods. .
제제화할 경우에는 통상 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 그러한 고형 제제는 유효성분에 적어도 하나 이상의 부형제, 예를 들면 전분, 칼슘 카르보네이트, 수크로스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데, 일반적으로 사용되는 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수용성용제, 현탁제, 유제, 동결건조 제제 및 좌제가 포함된다. 비수용성용제, 현탁제로는 프로필렌 글리콜, 폴리에틸렌 글리콜, 올리브유와 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and such solid preparations contain the active ingredient plus at least one excipient, such as starch, calcium carbonate, sucrose, lactose, and gelatin. It can be prepared by mixing etc. Additionally, in addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used diluents such as water and liquid paraffin, they contain various excipients such as wetting agents, sweeteners, fragrances, and preservatives. You can. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, tween 61, cacao, laurel, glycerogelatin, etc. can be used.
본 발명에 따른 약학 조성물은 개체에 다양한 경로로 투여될 수 있다. 투여의 모든 방식이 예상될 수 있는데, 예를 들면 경구, 정맥, 근육, 피하, 복강내 주사에 의해 투여될 수 있다.The pharmaceutical composition according to the present invention can be administered to an individual through various routes. All modes of administration are contemplated, for example, by oral, intravenous, intramuscular, subcutaneous, or intraperitoneal injection.
본 발명에 따른 약학 조성물의 투여량은 개체의 연령, 체중, 성별, 신체 상태 등을 고려하여 선택된다. 상기 약학 조성물 중 포함되는 유효성분의 농도는 대상에 따라 다양하게 선택할 수 있음은 자명하며, 바람직하게는 약학 조성물에 0.01 ~ 5,000 ㎍/ml의 농도로 포함되는 것이다. 그 농도가 0.01 ㎍/ml 미만일 경우에는 약학 활성이 나타나지 않을 수 있고, 5,000 ㎍/ml를 초과할 경우에는 인체에 독성을 나타낼 수 있다.The dosage of the pharmaceutical composition according to the present invention is selected taking into account the age, weight, gender, physical condition, etc. of the individual. It is obvious that the concentration of the active ingredient included in the pharmaceutical composition can be selected in various ways depending on the target, and is preferably included in the pharmaceutical composition at a concentration of 0.01 to 5,000 μg/ml. If the concentration is less than 0.01 ㎍/ml, pharmaceutical activity may not appear, and if it exceeds 5,000 ㎍/ml, it may be toxic to the human body.
상기 약학 조성물은 다양한 경구 또는 비경구 투여 형태로 제형화될 수 있다.The pharmaceutical composition may be formulated into various oral or parenteral dosage forms.
경구 투여용 제형으로는 예를 들면 정제, 환제, 경질, 연질 캅셀제, 액제, 현탁제, 유화제, 시럽제, 과립제 등이 있는데, 이들 제형은 유효성분 이외에 희석제(예: 락토즈, 덱스트로즈, 수크로즈, 만니톨, 솔비톨, 셀룰로즈 및/또는 글리신), 활택제(예: 실리카, 탈크, 스테아르산 및 그의 마그네슘 또는 칼슘염 및/또는 폴리에틸렌 글리콜)를 추가로 포함할 수 있다. 또한, 상기 정제는 마그네슘 알루미늄 실리케이트, 전분 페이스트, 젤라틴, 트라가칸스, 메틸셀룰로즈, 나트륨 카복시메틸셀룰로즈 및/또는 폴리비닐피롤리딘과 같은 결합제를 함유할 수 있으며, 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염과 같은 붕해제 또는 비등 혼합물 및/또는 흡수제, 착색제, 향미제 및 감미제를 함유할 수 있다. 상기 제형은 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.Dosage forms for oral administration include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. These dosage forms contain diluents (e.g. lactose, dextrose, water) in addition to the active ingredient. crose, mannitol, sorbitol, cellulose and/or glycine), lubricants (e.g. silica, talc, stearic acid and magnesium or calcium salts thereof and/or polyethylene glycol). Additionally, the tablets may contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and in some cases starch, agar, alginic acid. or disintegrants such as sodium salts thereof or effervescent mixtures and/or absorbents, colorants, flavoring and sweetening agents. The formulation can be prepared by conventional mixing, granulating or coating methods.
또한, 비경구 투여용 제형의 대표적인 것은 주사용 제제이며, 주사용 제제의 용매로서 물, 링거액, 등장성 생리식염수 또는 현탁액을 들 수 있다. 상기 주사용 제제의 멸균 고정 오일은 용매 또는 현탁 매질로서 사용할 수 있으며 모노-, 디-글리세라이드를 포함하여 어떠한 무자극성 고정오일도 이러한 목적으로 사용될 수 있다.In addition, representative formulations for parenteral administration are injectable formulations, and solvents for injectable formulations include water, Ringer's solution, isotonic saline solution, or suspension. The sterile fixed oil of the injectable preparation can be used as a solvent or suspending medium, and any non-irritating fixed oil, including mono- and di-glycerides, can be used for this purpose.
또한, 상기 주사용 제제는 올레산과 같은 지방산을 사용할 수 있다.Additionally, the injectable preparation may use fatty acids such as oleic acid.
이하, 준비예 및 실험예를 통하여 본 발명을 보다 자세히 설명한다. 다만, 상기 준비예 및 실험예는 본 발명에 대한 예시로 제시되는 것으로, 당업자에게 주지 저명한 기술 또는 구성에 대한 구체적인 설명이 본 발명의 요지를 불필요하게 흐릴 수 있다고 판단되는 경우에는 그 상세한 설명을 생략할 수 있고, 이에 의해 본 발명이 제한되지는 않는다. 본 발명은 후술하는 특허청구범위의 기재 및 그로부터 해석되는 균등 범주 내에서 다양한 변형 및 응용이 가능하다.Hereinafter, the present invention will be described in more detail through preparation examples and experimental examples. However, the above preparation examples and experimental examples are presented as examples of the present invention, and if it is judged that detailed descriptions of techniques or configurations well known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed descriptions are omitted. It can be done, and the present invention is not limited thereby. The present invention is capable of various modifications and applications within the description of the claims described below and the scope of equivalents interpreted therefrom.
<준비예 1> 모링가 콘카넨시스 추출물 제조<Preparation Example 1> Preparation of Moringa concanensis extract
건조된 모링가 콘카넨시스 원물을 100 g당 70% EtOH 1L와 혼합한 후, ultra sonicator를 이용해 99℃에서 2시간 중탕하여 추출물 내에 활성성분을 추출하였다. 중탕이 완료된 혼합물을 감압여과를 통해 걸러주어 여과하여 추출액을 얻었다. 여과된 추출액을 55℃의 항온수조에 넣고, 감압농축기를 통해 80~100mmHg의 압력을 주어 농축하였다. 농축이 끝난 추출액을 동결건조 시켜 사용하였다.The dried Moringa concanensis raw material was mixed with 1L of 70% EtOH per 100 g, and then boiled at 99°C for 2 hours using an ultra sonicator to extract the active ingredients in the extract. The mixture after the double boiling was filtered through reduced pressure filtration to obtain an extract. The filtered extract was placed in a constant temperature water bath at 55°C and concentrated by applying a pressure of 80 to 100 mmHg through a vacuum concentrator. The concentrated extract was freeze-dried and used.
<실험예 1> 모링가 콘카넨시스 추출물의 각질형성세포에서 항염증 효과 확인<Experimental Example 1> Confirmation of anti-inflammatory effect of Moringa concanensis extract on keratinocytes
모링가 콘카넨시스를 각질형성세포인 HaCaT cell에 처리하였을 때 독성을 끼치지 않는 농도를 확인하기 위해 MTT assay를 진행하였다. 그 결과, 300 μg/mL 이하의 농도에서 세포 독성을 나타내지 않았다(도 1).MTT assay was performed to confirm the non-toxic concentration when Moringa concanensis was treated with HaCaT cells, which are keratinocytes. As a result, it did not show cytotoxicity at concentrations below 300 μg/mL (Figure 1).
각질형성세포에서 모링가 콘카넨시스의 항염증 효과를 확인하고자 세포에 LPS(lipopolysaccharide)를 처리하여 염증반응을 유도하였다. Griess reagent와 ELISA kit를 이용해 염증매개인자인 NO 및 PGE2의 생성을 확인한 결과, 100과 300 μg/mL의 농도를 처리하였을 때 생성이 유의적으로 감소하였다(도 2).To confirm the anti-inflammatory effect of Moringa concanensis on keratinocytes, the cells were treated with lipopolysaccharide (LPS) to induce an inflammatory response. As a result of confirming the production of inflammatory mediators NO and PGE 2 using Griess reagent and ELISA kit, the production was significantly reduced when treated at concentrations of 100 and 300 μg/mL (Figure 2).
또한 NO 및 PGE2의 합성에 관여하는 효소인 iNOS와 COX-2의 발현을 PCR과 western blot으로 확인한 결과, mRNA와 protein 수준에서 발현이 유의적으로 감소하였다(도 3).In addition, the expression of iNOS and COX-2, enzymes involved in the synthesis of NO and PGE 2 , was confirmed by PCR and western blot, and the expression was significantly decreased at the mRNA and protein levels (Figure 3).
염증성사이토카인(TNF-α, IL-1β 및 IL-6)의 발현량 변화를 확인하기 위해 PCR과 ELISA kit로 확인한 결과, 모링가 콘카넨시스를 처리함으로써 mRNA와 protein 수준에서 TNF-α, IL-1β 및 IL-6의 발현량이 유의적으로 감소하였다(도 4).As a result of confirming changes in the expression level of inflammatory cytokines (TNF-α, IL-1β, and IL-6) using PCR and ELISA kits, treatment of Moringa concanensis showed that TNF-α and IL-6 were increased at the mRNA and protein levels. The expression levels of -1β and IL-6 were significantly decreased (Figure 4).
각질형성세포에서의 항염증 효과를 가지는 기전을 찾기 위해 NF-κB, MAPK 및 AP-1(activator protein-1)과 같은 전사인자의 인산화를 western blot으로 확인하였다. 그 결과, 모링가 콘카넨시스를 처리함에 따라 NF-κB, JNK 및 AP-1의 인산화를 유의적으로 억제시켜 각질형성세포에서 항염증 효과가 있는 것을 확인하였다(도 5).To find the mechanism of the anti-inflammatory effect in keratinocytes, phosphorylation of transcription factors such as NF-κB, MAPK, and AP-1 (activator protein-1) was confirmed by western blot. As a result, it was confirmed that treatment with Moringa concanensis significantly inhibited phosphorylation of NF-κB, JNK, and AP-1, resulting in an anti-inflammatory effect in keratinocytes (Figure 5).
<실험예 2> 모링가 콘카넨시스 추출물의 아토피 피부염 모델에서 치료 효과 확인<Experimental Example 2> Confirmation of therapeutic effect of Moringa concanensis extract in atopic dermatitis model
모링가 콘카넨시스 추출물의 아토피 피부염의 치료 효과를 확인하고자, 6주령 암컷 BALB/c 마우스에게 2,4-Dinitrochlorobenzene (DNCB)로 아토피 피부염을 유도하였다.To confirm the effectiveness of Moringa concanensis extract in treating atopic dermatitis, atopic dermatitis was induced in 6-week-old female BALB/c mice with 2,4-Dinitrochlorobenzene (DNCB).
면도 일을 0일차로 하여, 7일 동안 등과 오른쪽 귀에 1% DNCB로 처리하여 감작을 2회 진행하였다. 7일차부터 14일 간 모링가 콘카넨시스 추출물(실시예 1, 100 mg/kg; 실시예 2, 200 mg/kg)을 매일 경구투여 하였고, 격일로 0.6% DNCB를 등과 오른쪽 귀에 처리하여 아토피 피부염을 유지시켰다. 3일에 한 번씩 SCORAD 지수에 의거하여 아토피 피부염을 유도한 마우스의 증상을 점수로 측정하고, 체중, 귀 두께 및 수분 손실 정도를 측정하였다. 21일 차에는 부검을 통하여 장기(림프절, 비장)의 무게, 혈중 IgE 수치, 비만세포 침윤정도 및 조직학적 분석을 진행하였다(도 6).With shaving day being day 0, sensitization was performed twice by treating the back and right ear with 1% DNCB for 7 days. Moringa concanensis extract (Example 1, 100 mg/kg; Example 2, 200 mg/kg) was administered orally every day for 14 days from the 7th day, and 0.6% DNCB was treated every other day on the back and right ear to treat atopic dermatitis. was maintained. Once every three days, the symptoms of mice induced with atopic dermatitis were scored based on the SCORAD index, and body weight, ear thickness, and degree of water loss were measured. On the 21st day, an autopsy was performed to determine the weight of organs (lymph nodes, spleen), blood IgE level, degree of mast cell infiltration, and histological analysis (Figure 6).
그 결과, 모링가 콘카넨시스 추출물을 경구투여한 그룹에서 SCORAD 지수에 따른 dermatitis score(도 7), 귀 두께(도 8), 수분 손실 정도(도 9), 체중 변화(도 10), 혈중 IgE(도 11) 및 장기 무게(도 12)의 농도가 DNCB 단독 처리 그룹 대비 유의적으로 감소하였다. 또한, 조직학적 분석을 통해 추출물을 투여한 그룹에서 표피 두께 및 비만세포의 침윤이 DNCB 단독 처리 그룹 대비 유의적으로 감소하였다(도 13 내지 15).As a result, in the group administered orally the Moringa concanensis extract, dermatitis score according to the SCORAD index (Figure 7), ear thickness (Figure 8), degree of water loss (Figure 9), weight change (Figure 10), and blood IgE (FIG. 11) and organ weight (FIG. 12) concentrations were significantly decreased compared to the DNCB treatment group alone. In addition, through histological analysis, the epidermal thickness and mast cell infiltration in the group administered the extract were significantly reduced compared to the group treated with DNCB alone (FIGS. 13 to 15).
결과적으로, DNCB로 아토피 피부염을 유도한 마우스에서, 모링가 콘카넨시스 주정 추출물을 경구투여한 그룹은 양성대조군으로 사용된 스테로이드계 치료제 (dexamethasone, 비교예)에서 보인 체중 감소와 같은 부작용이 없음을 확인하였다. 또한, 스테로이드계 치료제와 비교했을 때 혈중 IgE 감소, 귀 두께 감소 및 수분 손실 개선 등 효과가 동등 혹은 그 이상으로 아토피 피부염 증상이 개선되는 것을 확인하였다.As a result, in mice in which atopic dermatitis was induced with DNCB, the group administered orally with Moringa concanensis alcohol extract did not have side effects such as weight loss seen with the steroid-based treatment (dexamethasone, comparative example) used as a positive control group. Confirmed. In addition, compared to steroid-based treatments, it was confirmed that atopic dermatitis symptoms were improved to an equal or greater level, including reduction of blood IgE, reduction of ear thickness, and improvement of moisture loss.
<실험예 3> 모링가 콘카넨시스 추출물의 추출 용매별 항염증 효과 비교<Experimental Example 3> Comparison of anti-inflammatory effects of Moringa concanensis extract by extraction solvent
상기의 실험예 1 및 2에서는 모링가 콘카넨시스의 아토피 개선 효과를 확인하였다. 추출물을 제조 시 추출용매의 종류와 농도에 따라 추출되는 유효성분들이 상이해지고, 이에 따른 효과도 달라지므로 본 실험에서는 모링가 콘카넨시스에 물, 30% 에탄올, 70% 에탄올을 이용하여 항염증 효과를 테스트 하였다. 추출물의 제조방법은 위의 준비예 1과 같은 방식으로 제조하였다.In Experimental Examples 1 and 2 above, the atopy improvement effect of Moringa concanensis was confirmed. When manufacturing the extract, the extracted active ingredients differ depending on the type and concentration of the extraction solvent, and the resulting effect also varies. Therefore, in this experiment, water, 30% ethanol, and 70% ethanol were used for Moringa concanensis to determine the anti-inflammatory effect. was tested. The extract was prepared in the same manner as Preparation Example 1 above.
그 결과 도 16에서와 같이 각질형성세포(HaCaT cell)에 LPS로 유도하였을 때, 모링가 콘카넨시스 30% 및 70% 주정(에탄올) 추출물, 특히 70% 주정(에탄올) 추출물은 NO 생성을 유의적으로 감소시킴을 확인하였다. 하지만, 모링가 콘카넨시스 열수 추출물은 오히려 NO 생성을 증가시키는 것을 확인하였다. 따라서, 추출 방법을 비교하였을 때 추출용매로써 열수 또는 30% 주정을 사용한 것 보다 70%주정을 사용한 추출물의 항염증 효능이 보다 우수한 것을 확인하였다.As a result, as shown in Figure 16, when keratinocytes (HaCaT cells) were induced with LPS, the 30% and 70% alcohol (ethanol) extracts of Moringa concanensis, especially the 70% alcohol (ethanol) extract, produced NO. It was confirmed that it was significantly reduced. However, it was confirmed that Moringa concanensis hot water extract actually increased NO production. Therefore, when comparing extraction methods, it was confirmed that the anti-inflammatory effect of the extract using 70% alcohol was better than that using hot water or 30% alcohol as the extraction solvent.
<실험예 4> 모링가 콘카넨시스 부위별 세포독성평가 및 항염증 효과 비교<Experimental Example 4> Cytotoxicity evaluation and anti-inflammatory effect comparison for each part of Moringa concanensis
동일한 식물이라 하더라도 그 부위에 따라 포함하고 있는 유효성분들이 상이하고, 이에 따른 효과도 달라지므로, 본 실험에서는 모링가 콘카넨시스의 부위별(잎 또는 줄기껍질) 세포독평가 및 항염증 효과를 비교해 보았다. 모링가 콘카넨시스의 잎(leaf)과 줄기껍질(bark)을 이용하여 추출물을 제조하였고, 제조방법은 위의 준비예 1과 같은 방식으로 제조하였다.Even if it is the same plant, the active ingredients it contains are different depending on the part, and the effect varies accordingly. Therefore, in this experiment, the cytotoxicity evaluation and anti-inflammatory effect of each part (leaf or stem bark) of Moringa concanensis were compared. saw. An extract was prepared using the leaves and bark of Moringa concanensis, and the preparation method was the same as Preparation Example 1 above.
그 결과 도 17에서와 같이 모링가 콘카넨시스의 잎(leaf)과 줄기껍질(bark)의 세포독성평가를 한 결과 잎의 경우 300 μg/mL 이하의 농도에서 세포독성이 없었고, 줄기껍질의 경우 30 μg/mL 이상에서 독성이 있는 것을 확인하였다. 항염증 효과를 확인해 보기위해 모링가 콘카넨시스 잎 추출물과 줄기껍질 추출물의 NO 생성을 평가한 결과, 잎 추출물의 경우 100 μg/mL 이상의 농도에서 NO 생성을 유의적으로 감소시켰고, 줄기껍질 추출물의 경우 오히려 NO 생성을 증가시키는 것을 확인하였다. 즉, 모링가 콘카넨시스의 잎 추출물은 줄기껍질 추출물 대비 낮은 세포독성과 우수한 항염증 효과 확인한 것이다.As a result, as shown in Figure 17, as a result of evaluating the cytotoxicity of the leaves and stem bark of Moringa concanensis, there was no cytotoxicity in the leaves at a concentration of 300 μg/mL or less, and in the case of the stem bark It was confirmed to be toxic above 30 μg/mL. To confirm the anti-inflammatory effect, NO production was evaluated from Moringa concanensis leaf extract and stem bark extract. As a result, the leaf extract significantly reduced NO production at concentrations above 100 μg/mL, and the stem bark extract significantly reduced NO production at concentrations above 100 μg/mL. In this case, it was confirmed that NO production actually increased. In other words, the leaf extract of Moringa concanensis was confirmed to have lower cytotoxicity and superior anti-inflammatory effects compared to the stem bark extract.
이상에서 살펴본 바와 같이, 본 발명은 상기에 언급된 바람직한 실시예로서 설명되었으나, 본 발명 분야의 통상의 기술자들은 동일한 기술적 범위 내에서 다른 구성요소를 추가, 변경, 삭제 등을 통하여, 퇴보적인 다른 발명이나 본 발명 사상의 범위 내에 포함되는 다른 실시예를 용이하게 제안할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 본 발명의 범위를 한정하는 것이 아니다.As seen above, the present invention has been described as the preferred embodiment mentioned above, but those skilled in the art will find that other regressive inventions can be found by adding, changing, deleting, etc. other components within the same technical scope. However, other embodiments that are included within the scope of the present invention can be easily proposed. Therefore, the embodiments described above are illustrative in all respects and do not limit the scope of the present invention.
Claims (10)
상기 모링가 콘카넨시스 추출물은 세포 독성이 없는 것인, 아토피의 예방 또는 개선용 화장료 조성물.According to paragraph 1,
A cosmetic composition for preventing or improving atopy, wherein the Moringa concanensis extract is non-cytotoxic.
상기 조성물은 NO 및 PGE2 생성을 억제시키는 것인, 아토피의 예방 또는 개선용 화장료 조성물.According to paragraph 1,
The composition is a cosmetic composition for preventing or improving atopy, which inhibits NO and PGE 2 production.
상기 조성물은 iNOS와 COX-2의 발현을 억제시키는 것인, 아토피의 예방 또는 개선용 화장료 조성물.According to paragraph 1,
The composition is a cosmetic composition for preventing or improving atopy, which inhibits the expression of iNOS and COX-2.
상기 조성물은 TNF-α, IL-1β 및 IL-6의 발현을 억제시키는 것인, 아토피의 예방 또는 개선용 화장료 조성물.According to paragraph 1,
The composition is a cosmetic composition for preventing or improving atopy, which inhibits the expression of TNF-α, IL-1β and IL-6.
상기 조성물은 NF-κB, JNK 및 AP-1의 인산화를 억제시키는 것인, 아토피의 예방 또는 개선용 화장료 조성물.According to paragraph 1,
The composition is a cosmetic composition for preventing or improving atopy, which inhibits phosphorylation of NF-κB, JNK and AP-1.
상기 조성물은 혈중 IgE 농도를 감소시키는 것인, 아토피의 예방 또는 개선용 화장료 조성물.According to paragraph 1,
The composition is a cosmetic composition for preventing or improving atopy, which reduces the concentration of IgE in the blood.
상기 모링가 콘카넨시스 추출물은 모링가 콘카넨시스의 잎 부분을 추출한 것인, 아토피의 예방 또는 개선용 화장료 조성물.According to paragraph 1,
The Moringa concanensis extract is a cosmetic composition for preventing or improving atopy, which is obtained by extracting the leaf part of Moringa concanensis.
A pharmaceutical composition for preventing or treating atopy containing Moringa concanensis extract as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220068108A KR20230167897A (en) | 2022-06-03 | 2022-06-03 | Composition for the prevention, improvement or treatment of atopy comprising Moringa concanensis L. as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220068108A KR20230167897A (en) | 2022-06-03 | 2022-06-03 | Composition for the prevention, improvement or treatment of atopy comprising Moringa concanensis L. as an active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230167897A true KR20230167897A (en) | 2023-12-12 |
Family
ID=89159689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220068108A KR20230167897A (en) | 2022-06-03 | 2022-06-03 | Composition for the prevention, improvement or treatment of atopy comprising Moringa concanensis L. as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20230167897A (en) |
-
2022
- 2022-06-03 KR KR1020220068108A patent/KR20230167897A/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190090363A (en) | Cosmetic composition comprising mixture of fermented extract of Cirsium japonicum and Moringa oleifera | |
| KR20160056268A (en) | Composition for the inhibition of UV-induced melanogenesis or anti inflammatory comprising extracts or fractions of Psidium guajava L. | |
| KR20170046364A (en) | Composition for skin whitening comprising fraction of fruit extract of Sageretia thea as effective component | |
| KR102425559B1 (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
| KR102070789B1 (en) | Composition for ameliorating or treating acne comprising Salvia plebeia extract and its fraction as effective component | |
| KR100894714B1 (en) | Extract of humata tyermanni moore having skin whitening and anti-oxidative activation | |
| KR102234199B1 (en) | Composition for preventing hair loss or promoting hair growth comprising the compound isolated from Alpinia galanga extract and Alpinia galanga extract as an active ingredient | |
| KR20230167897A (en) | Composition for the prevention, improvement or treatment of atopy comprising Moringa concanensis L. as an active ingredient | |
| KR102095265B1 (en) | Composition for preventing, treating or improving of atopic dermatitis comprising edible insects based oil as an effective ingredient | |
| KR101721666B1 (en) | Skin-whitening compound from Inula britannica, and skin-whitening composition containing the same | |
| KR100959545B1 (en) | Compositions for Improving Skin Conditions | |
| KR102379555B1 (en) | Composition for the prevention and treatment of skin ailment, including Pleurotus cornucopiae and Rehmannia glutinosa complex extract as an active ingredient | |
| KR102315709B1 (en) | Composition for skin whitening containing lobetyolin | |
| KR102262362B1 (en) | Composition for improving skin conditions comprising an extract of oriental melon stem or cucumber stem | |
| KR102157755B1 (en) | Composition for anti-inflammatory or anti-atopic containing Uncarina stellulifera extracts | |
| KR102680332B1 (en) | Composition with antioxidant, whitening and antibacterial activity comprising extracts of Torreya nucifera leaves and branches as an active ingredient | |
| KR102415077B1 (en) | Composition for preventing skin aging comprising anemone rivularis extract | |
| KR102569019B1 (en) | Composition comprising centella asiatica extract treated with pulsed electric field | |
| KR102406982B1 (en) | Composition for improving dermatitis comprising extract of Antennaria dioica having antioxidant activity as effective component | |
| KR102443334B1 (en) | Composition with Anti-Inflammation, Skin Moisturizing, Pruritis Improving, and Skin Regeneration Property Comprising Complex Extract of Hibiscus Syriacus as Active Ingredient | |
| KR102177221B1 (en) | Anti-inflammatory composition containing mixed extracts of fermented Gentianae scabrae Radix, Chrysanthemum indicum and Mentha piperascens | |
| KR101022258B1 (en) | Compositions for Improving Skin Conditions Comprising Extract of Phlomis umbrosa | |
| KR102198355B1 (en) | Pharmaceutical composition comprising Cymbidium extracts for preventing or treating allergic diseases or contact | |
| KR101907918B1 (en) | Manufacturing method of ginseng extract residue for preventing or improving skin wrinkle using acidic solution | |
| KR20220152929A (en) | Cosmetic composition for improving atopy comprising angelica tenuissima fermented extracts as an active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal |